Chapter 25: Child and Adolescent Psychopharmacology

Child and adolescent psychopharmacology addresses the specialized considerations required when prescribing psychiatric medications to younger populations, a domain that differs significantly from adult pharmacological practice. The chapter examines fundamental developmental differences in how children process and metabolize medications, requiring adjusted dosing strategies and heightened awareness of side effect profiles that may manifest differently than in adult patients. A central theme involves the integration of pharmacological and psychotherapeutic approaches, recognizing that medication alone is rarely sufficient for optimal treatment outcomes in pediatric populations. The chapter discusses attention deficit hyperactivity disorder treatment options, including stimulant and non-stimulant medications alongside behavioral interventions, establishing a framework for comprehensive care. Depression and suicidality in children receives detailed attention, particularly the controversial black-box warning associated with selective serotonin reuptake inhibitors and the clinical complexities of monitoring mood changes during early treatment phases. The distinction between childhood bipolar disorder and attention deficit hyperactivity disorder is explored, as diagnostic confusion frequently occurs and leads to inappropriate medication selection. Anxiety disorders in children are addressed through multiple treatment modalities, weighing the benefits and risks of serotonergic medications, benzodiazepines, and evidence-based behavioral therapies. The chapter emphasizes informed consent and family education as critical ethical components, ensuring caregivers understand medication rationale, expected timelines for therapeutic response, and potential adverse effects. Throughout, the reality that long-term developmental outcomes from pediatric psychotropic medication exposure remain inadequately researched is acknowledged, creating ongoing clinical uncertainty and the necessity for individualized risk-benefit analysis in each case.